Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio
Genmab A/S (NASDAQ: GMAB) announced it will discontinue clinical development of acasunlimab, a PD‑L1 x...
2026
NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support
The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged...
Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy
Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making...
China State Council Approves Revised Drug Administration Regulations, Accelerating Innovation Review
The State Council of China approved the Revised Draft of the Implementation Regulations of the...